SCHEMBL4902072

SCHEMBL4902072

Cc1ccc(Cn2c(-c3cccc(-c4cccc(NC(=O)O)c4)c3)cc(C(F)(F)F)c(C#N)c2=O)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RXRA P19793 3/20 0.46
NR1H2 P55055 3/20 0.46
NR1H3 Q13133 3/20 0.46
RXFP1 Q9HBX9 3/20 0.40
MAPT P10636 3/20 0.40
TP53 P04637 2/20 0.40
KDM4E B2RXH2 3/20 0.39
THRB P10828 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TNKS O95271 7/20 0.37
TNKS2 Q9H2K2 7/20 0.37
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ALDH1A1 P00352 2/20 0.36
EPHX2 P34913 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14184090 0.93 RXRA (0.44) RXRANR1H2NR1H3RXFP1MAPT
SCHEMBL4905290 0.92 RXRA (0.43) RXRANR1H2NR1H3RXFP1MAPT
SCHEMBL4904313 0.91 RXRA (0.42) RXRANR1H2NR1H3KDM4ENPC1
SCHEMBL4905525 0.88 NR1H2 (0.46) RXRANR1H2NR1H3MAPTKDM4E
SCHEMBL4901943 0.88 RXRA (0.40) RXRANR1H2NR1H3NPC1RAB9A
SCHEMBL4905566 0.87 RXRA (0.62) RXRANR1H2NR1H3RXFP1MAPT
SCHEMBL14184095 0.87 RXRA (0.40) RXRANR1H2NR1H3RXFP1MAPT
SCHEMBL4901856 0.87 NR1H2 (0.47) RXRANR1H2NR1H3MAPTKDM4E
SCHEMBL4905068 0.86 RXRA (0.42) RXRANR1H2NR1H3RXFP1MAPT
SCHEMBL4902420 0.86 RXRA (0.39) RXRANR1H2NR1H3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US claimed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO claimed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 RXRA 20/4885NR1H2 1/4885NR1H3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.